On May 29, 2025 Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, reported that members of the Replimune management team will present in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 4:20 PM ET (Press release, Replimune, MAY 29, 2025, View Source [SID1234653487]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A simultaneous webcast will be available in the Investors section of Replimune’s website at replimune.com. A replay will be available for 30 days following the conference.

On May 29, 2025 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging advanced AI and machine learning to transform the cost, pace, and timeline of oncology drug development, reported promising preclinical data for LP-184 in atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive pediatric brain cancer (Press release, Lantern Pharma, MAY 29, 2025, View Source [SID1234653502]). The results were presented by Dr. Eric Raabe of Johns Hopkins University School of Medicine at the Society for Neuro-Oncology’s 8th Biennial Pediatric Neuro-Oncology Conference held May 15-17, 2025, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data further validates the research that supported Lantern Pharma’s Rare Pediatric Disease Designation from the FDA for LP-184 in ATRT and strengthens the scientific foundation for the company’s planned pediatric clinical trial expected to begin in late 2025 or early 2026.

The data demonstrated that LP-184, a next-generation acylfulvene clinical-stage drug candidate, significantly extended survival in mouse models of ATRT. In the CHLA06 model, median survival increased from 20 days in the control group to 89 days in the LP-184 treatment group, representing a 345% improvement (p<0.0001). In the BT37 model, median survival increased from 68 days to 98 days (p=0.0422).

"The preclinical data presented by Dr. Raabe and his team at Johns Hopkins provides powerful confirmation of LP-184’s potential to address the significant unmet need in pediatric ATRT," said Panna Sharma, CEO and President of Lantern Pharma. "The substantial increase in survival time and the favorable tolerability profile observed in these models underscore the promise of LP-184 as a novel therapeutic option to evaluate clinically for this devastating pediatric cancer. This independent validation further supports our Rare Pediatric Disease Designation and reinforces our path toward initiating our planned pediatric clinical trial."

Key highlights from the presentation include:

LP-184 demonstrated potent anti-tumor activity across multiple ATRT cell lines representing different molecular subtypes (MYC, TYR, and SHH), with IC50 values ranging from 17.5 nM to 161 nM
Treatment with LP-184 significantly decreased cancer cell proliferation and increased apoptosis (programmed cell death) in ATRT cells
LP-184 showed strong blood-brain barrier penetrance, with reported Cmax of 730 nM in brain tissue
No apparent toxicity was observed in the mouse models, with stable weight maintained throughout the treatment period
Treatment with LP-184 resulted in statistically significant survival benefits in two different orthotopic xenograft ATRT models
ATRT is characterized by the deletion or inactivation of the SMARCB1 gene, an epigenetic regulator. LP-184’s mechanism of action may be particularly effective against tumors with epigenetic dysregulation, potentially explaining the strong preclinical anti-tumor activity observed in this tumor type.

"Current treatment options for ATRT are limited to surgery, intensive chemotherapy, and radiation, with poor outcomes and significant treatment-related toxicity," said Dr. Marc Chamberlain, Chief Medical Officer of Starlight Therapeutics and Lantern Executive Director of Clinical Development. "The single-agent activity of LP-184 in these models suggests it could potentially transform the treatment landscape for children with these brain tumors."

The company highlighted that the pediatric Phase I trial for LP-184 in brain tumors is targeted to open in winter 2025 or early 2026, following completion of the ongoing Phase I trial in adult solid tumors (NCT05933265) and obtaining future funding and approvals from the pediatric consortium.

About Atypical Teratoid Rhabdoid Tumor (ATRT)

ATRT is a rare, fast-growing tumor of the brain and spinal cord that typically occurs in children aged three years and younger, though it can occur in older children and adults. These tumors are characterized by the loss of function of the SMARCB1 gene. ATRTs account for approximately 1-2% of all pediatric brain tumors but represent a disproportionately high percentage of brain tumors in infants. Current treatment involves a combination of surgery, intensive chemotherapy, and, in some cases, radiation therapy. Despite aggressive treatment, the prognosis remains poor, with a median survival of approximately 17 months, highlighting the urgent need for more effective therapies.

About LP-184

LP-184 is a next-generation acylfulvene drug candidate, a synthetic small molecule belonging to a class of naturally-derived anti-cancer agents. LP-184 works by preferentially damaging DNA in cancer cells that overexpress specific biomarkers or that harbor mutations in DNA damage repair pathways. LP-184 is the product of years of research, including insights from RADR, Lantern’s proprietary AI platform that leverages over 200 billion oncology-focused data points.

LP-184 is a prodrug that is converted to its bioactive form inside the cancer cell by PTGR1 (prostaglandin reductase 1), an enzyme that is overexpressed in certain cancers. Once activated, LP-184 creates cytotoxic metabolites that form adducts with DNA, leading to irreparable DNA damage and ultimately tumor cell death.

LP-184 has shown nanomolar preclinical potency across multiple cancer types, including several that are resistant to standard therapies, and has demonstrated particularly promising preclinical activity in CNS and brain cancers. The drug has received Orphan Drug Designation from the FDA for the treatment of malignant gliomas and pancreatic cancer, as well as Rare Pediatric Disease Designation for ATRT.

On May 29, 2025 Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, reported that management will present at the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 4-5, 2025, to discuss the company’s pipeline, platform, and business strategy (Press release, Immuneering, MAY 29, 2025, View Source [SID1234653488]). Participating will be Ben Zeskind, Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Brett Hall, Chief Scientific Officer, Harold "E.B." Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Format: Company Presentation and 1×1 Investor Meetings

Date/Time: June 5 from 12:50 – 1:20 pm ET

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

On May 29, 2025 Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, reported that it will showcase its latest research highlights through more than 155 accepted abstracts and presentations at the 2025 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, held in Chicago from May 30-June 3, 2025 (Press release, Sarah Cannon Research Institute, MAY 29, 2025, View Source [SID1234653503]). Over 75 investigators from more than 20 research sites in SCRI’s network are first authors and co-authors on the clinical trial updates featured at the Annual Meeting, including findings from 55 early-phase clinical trials.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to join our colleagues from around the world at ASCO (Free ASCO Whitepaper)’s Annual Meeting to share the latest developments in research that are advancing therapies for patients," says Howard A. "Skip" Burris, III, MD, President, SCRI. "From developments in novel agents to findings in a variety of cancers, the research presented by SCRI leaders not only highlights how our work is accelerating drug development, but also our dedication to ensuring people facing cancer have access to innovative treatments closer to home."

For a comprehensive list of SCRI abstracts and presentations, visit SCRI’s ASCO (Free ASCO Whitepaper) Site. To learn more about our research experts, visit our Leadership Page.

Noteworthy Presentations

Blood Cancer

David Andorsky, MD, SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, will present "Efficacy and Safety of Asciminib in Patients with Chronic-Phase Chronic Myeloid Leukemia after 1 Tyrosine Kinase Inhibitor: Interim Analysis of the Phase 2 ASC2ESCALATE Trial" in the Rapid Oral Abstract Session, Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant on Friday, May 30 at 2:06 p.m. CDT in E450a.
Breast Cancer

Erika Hamilton, MD, SCRI, will deliver two oral presentations, including "Vepdegestrant, a PROTAC Estrogen Receptor Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 –Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 Study" in the Oral Abstract Session, Breast Cancer—Metastatic on Saturday, May 31 at 1:15 p.m. CDT in Hall B1 and "Initial Phase 1 Dose Escalation Data for Emiltatug Ledadotin, a Novel B7-H4-Directed Dolasynthen Antibody-Drug Conjugate" during the Rapid Oral Abstract Session, Development Therapeutics—Molecularly Targeted Agents and Tumor Biology on Monday, June 2 at 8:00 a.m. CDT in S406.
Cancer Detection

Dax Kurbegov, MD, HCA Healthcare Sarah Cannon Cancer Network, will present "Performance Evaluation of a Reflex Blood-Based Methylated ctDNA Multi-Cancer Early Detection Test in Individuals with Obesity" in the Clinical Science Symposium, The Future of Cancer Detection is Coming on Saturday, May 31 at 8:24 a.m. CDT in Hall D1.
Lung Cancer

David Spigel, MD, SCRI, will present "An International, Multicenter, Prospective Randomized Trial of Adjuvant Chemotherapy for Stage Ia-IIa Non-Small Cell Lung Cancer Identified as High-Risk by a 14-Gene Molecular Assay" in the Poster Session, Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers on Saturday, May 31 from 1:30 – 4:30 p.m. CDT in Hall A.
Solid Tumors

Judy Wang, MD, SCRI at Florida Cancer Specialists & Research Institute, will deliver "An Open-Label, Phase I Trial of The SIRPα Monoclonal Antibody, BI 770371, Alone and in Combination with The PD-1 Inhibitor Ezabenlimab in Patients with Advanced Solid Tumors" as part of the Rapid Oral Abstract Session, Development Therapeutics—Immunotherapy on Sunday, June 1 at 11:45 a.m. CDT in S406.
In addition to the above, Dr. Erika Hamilton and Dr. David Spigel will serve in two prestigious leadership roles, as 2025 ASCO (Free ASCO Whitepaper) Annual Meeting Scientific Program Committee Chair and Cancer Communications Committee Chair, respectively.

In addition to scientific presentations, SCRI leadership will participate in and lead ASCO (Free ASCO Whitepaper) sessions, including:

Jason Henry, MD, SCRI at HCA HealthONE, will chair the Oral Abstract Session, Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology, on Friday, May 30 from 2:45 – 5:45 p.m. CDT in Hall D1.
Elisa Fontana, MD, PhD, SCRI at HCA Healthcare UK, will serve as panelist and present "KRAS G12C: From First to Next Generation" as part of the Gastrointestinal Cancer—Colorectal and Anal Oral Abstract Session on Friday, May 30 at 5:21 p.m. CDT in Arie Crown Theater.
Dr. Dax Kurbegov will serve as panelist in The Future of Cancer Detection Is Coming on Saturday, May 31 from 8:00 – 9:30 a.m. CDT in Hall D1.
Dr. Howard Burris will deliver the "Top Donor Recognition Ceremony" during the Opening Session on Saturday, May 31 at 10:50 a.m. CDT in Hall B1.
Haydar Frangoul, MD, MS, SCRI at TriStar Centennial Children’s Hospital, will present "Established Gene Therapy Options in the Clinic" during the ASCO (Free ASCO Whitepaper)/AACR Joint Session: Lessons From Gene Therapy in Practice: Successes, Challenges, and How to Have Access for All on Saturday, May 31 at 1:19 p.m. CDT in E450a.
Dr. Erika Hamilton will serve as a panelist in the Oral Abstract Session, Breast Cancer—Metastatic on Saturday, May 31 from 1:15 – 4:15 p.m. in Hall B1.
Meredith Pelster, MD, MSCI, SCRI, will chair the Oral Abstract Session, Development Therapeutics—Immunotherapy on Saturday, May 31 from 3:00 – 6:00 p.m. CDT in Hall D2.
Abdul Rafeh Naqash, MD, SCRI at OU Health Stephenson Cancer Center, will present "Dual-Edged: The Promise and Perils of Bispecific T-Cell Engagers in Lung Cancer and Beyond" during BiTES and Beyond: BiTES, Amivantimab, and the Multidimensional Impact of Toxicity Management on Sunday, June 1 at 11:42 a.m. CDT in Arie Crown Theater.
Melissa Johnson, MD, SCRI, will present "Gizmos and Gadgets! How Can Community Oncology Practices Hurdle the Obstacles to Administering Lung Cancer’s Newest Therapies" during BiTES and Beyond: BiTES, Amivantimab, and the Multidimensional Impact of Toxicity Management on Sunday, June 1 at 12:06 p.m. CDT in Arie Crown Theater.
Dr. Erika Hamilton will chair the Plenary Session on June 1 from 1:00 – 4:00 p.m. CDT in Hall B1.
Dr. Erika Hamilton will serve as a panelist in the Rapid Oral Abstract Session, Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology on Monday, June 2 from 8:00 – 9:30 a.m. CDT in S406.
Meredith McKean, MD, MPH, SCRI, will present "Novel Targets in Melanoma Treatment" during State of the Art: Melanoma 3.0T—Tech Innovations, New Targeted Therapies, and T-Cell Breakthroughs on Tuesday, June 3 at 8:15 a.m. CDT in S100a.
Dr. Abdul Rafeh Naqash will chair the Oral Abstract Session, Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers on Monday, June 2 from 3:00 – 6:00 p.m. CDT in Arie Crown Theater.
Additional Poster Presentations with SCRI First Authors

Saturday, May 31

"Phase 1 Expansion Study of FF-10832 Antitumor Activity in Patients with Advanced Biliary Carcinomas," Gerald Falchook, MD, SCRI at HCA HealthONE, 9:00 a.m. – 12:00 p.m. CDT, Hall A.
"Preliminary Safety, Pharmacokinetics, and Clinical Activity of RG6344 in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer," Dr. Elisa Fontana, 9:00 a.m. – 12:00 p.m. CDT, Hall A.
"Real-World Treatment Patterns and Outcomes with Trifluridine/Tipiracil Monotherapy or in Combination with Bevacizumab in Metastatic Colorectal Cancer," Donald Richards, MD, PhD, SCRI at Texas Oncology I The US Oncology Network, 9:00 a.m. – 12:00 p.m. CDT, Hall A.
"Interim Results of PDL1V, a Vedotin-Based ADC Targeting PD-L1, in Patients with NSCLC in a Phase 1 Trial," Dr. Elisa Fontana, 1:30 – 4:30 p.m. CDT, Hall A.
"Integration of a Virtual Personalized Medicine Review Board Integration into a Major Community Oncology Phase 1 Unit," Marilynn Hammer, PhD, SCRI, 1:30 – 4:30 p.m. CDT, Hall A.
"A Digital Intervention to Enhance Engagement with Oral Oncolytic Treatments and Assess Patient Experiences with Novel Therapies," David Waterhouse, MD, MPH, SCRI at OHC I The US Oncology Network, 1:30 – 4:30 p.m. CDT, Hall A.
Monday, June 2

"Efficacy and Safety of Larotrectinib in Patients with TRK Fusion Thyroid Carcinoma: An Updated Analysis," Marcia Brose, MD, PhD, SCRI at Sidney Kimmel Cancer Center at Jefferson Health, 9:00 a.m. – 12:00 p.m. CDT, Hall A.
"Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Safety Analyses from the Phase III EMBER-3 Trial," Joyce O’Shaughnessy, MD, SCRI at Texas Oncology I The US Oncology Network, 9:00 a.m. – 12:00 p.m. CDT, Hall A.
"Zanzalintinib + Nivolumab ± Relatlimab in Patients with Advanced Solid Tumors: Results from Two Dose-Escalation Cohorts of the Phase 1b STELLAR 002 Study," Benjamin Garmezy, MD, SCRI, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
"First Report of ROR2 Directed Therapy with Conditionally Active Antibody Drug Conjugate in Advanced Melanoma," Jacob Keeling, MD, SCRI at HCA HealthONE, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
"ZL-1310, a DLL3 ADC, in Patients with Extensive Stage Small Cell Lung Cancer: Ph1 Trial Update," Manish Patel, MD, SCRI at Florica Cancer Specialists & Research Institute, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
"First-in-Human Phase 1 Study of CUSP06, a Cadherin-6-Directed Antibody-Drug Conjugate, in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors," Dr. Manish Patel, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
"First-in-Human Study of BG-C9074, a B7-H4-Targeting ADC in Patients with Advanced Solid Tumors: Preliminary Results of the Dose-Escalation Phase," Cesar Perez, MD, SCRI at Florida Cancer Specialists & Research Institute, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
"Efficacy and Safety of Pralsetinib in RET Fusion-Positive Solid Tumors: Final Data from the ARROW Trial," Vivek Subbiah, MD, 1:30 p.m. – 4:30 p.m. CDT, Hall A.
"Efficacy and Safety Results of a Multi-Center Phase I Study of Utidelone Capsule, a Novel Oral Microtubule Inhibitor, in Advanced Solid Tumor Patients," Dr. Judy Wang, 1:30 p.m. – 4:30 p.m. CDT, Hall A.

On May 29, 2025 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, reported that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences (Press release, Syndax, MAY 29, 2025, View Source [SID1234653489]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference with a fireside chat on Thursday, June 5, 2025, at 1:25 p.m. ET.
Goldman Sachs 46th Annual Global Healthcare Conference with a fireside chat on Wednesday, June 11, 2025, at 2:00 p.m. ET.
A live webcast of the fireside chats will be available in the Investor section of the Company’s website at www.syndax.com, where a replay will also be available for a limited time.